May 06, 2023
Source:
Presented at the 13 th C1-inhibitor Deficiency and Angioedema Workshop Budapest (Hungary), 4–7 May 2023
Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate Release Capsule (PHVS416) in Treatment of Hereditary Angioedema Attacks: Topline Results of RAPIDe 1 Phase 2 Trial
May 06, 2023
Source:
Presented at the 13th C1-inhibitor Deficiency and Angioedema Workshop Budapest (Hungary), 4–7 May 2023
Efficacy of the oral bradykinin B2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) by attack location in the RAPIDe-1 phase 2 clinical trial for treatment of hereditary angioedema attacks
May 06, 2023
Source:
Presented at the 13th C1-inhibitor Deficiency and Angioedema Workshop Budapest (Hungary), 4–7 May 2023
The EC85 Derived from the Oral Bradykinin B2 Receptor Antagonist Deucrictibant (PHA121) Against Bradykinin Effects in Healthy Volunteers Predicts the Onset and Duration of Its Clinical Effects in Hereditary Angioedema
May 06, 2023
Source:
Presented at the 13 th C1-inhibitor Deficiency and Angioedema Workshop Budapest (Hungary), 4–7 May 2023
Cardiovascular safety of the orally administered bradykinin B2 receptor antagonist, deucrictibant (PHA121, PHA-022121)
May 05, 2023
Source:
Presented at the 13 th C1-inhibitor Deficiency and Angioedema Workshop Budapest (Hungary), 4–7 May 2023
Early symptom relief following treatment with the oral bradykinin 2 receptor antagonist deucrictibant immediate-release capsule (PHVS416) in patients with hereditary angioedema attacks
Mar 18, 2023
Source:
Presentated at 2023 HAEi Regional Conference APAC. Bangkok, Thailand – 17-19 March 2023
Efficacy and Safety of Bradykinin B2 Receptor Inhibition with Oral PHVS416 in Treating Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial
Feb 26, 2023
Source:
Presented at the 2023 American Academy of Allergy Asthma and Immunology Annual Meeting (AAAAI 2023) San Antonio, TX, USA; February 24–27, 2023
Efficacy and Safety of Bradykinin B2 Receptor Inhibition with Oral PHVS416 in Treating Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial
Nov 13, 2022
Pharmacokinetics of PHVS719, extended-release tablet formulation of PHA121, a first-in-class oral human bradykinin B2-receptor antagonist
Nov 12, 2022
Development of PHVS719: an Oral Extended-Release Bradykinin B2 Receptor Antagonist to Prevent Hereditary Angioedema Attacks
Oct 07, 2022
Development of two novel oral formulations of a first in class bradykinin B2 receptor antagonist for on demand and prophylactic treatment of hereditary angioedema
Sep 16, 2022
Source:
Presented at Bradykinin Symposium 2022. Berlin, Germany – 15-16 September 2022
Development of PHA121 for On-Demand and Prophylactic Treatment of HAE
Jun 07, 2022
Source:
Presented at Satellite Symposium Kinin 2022, June 7
Tailored drug development for patients living with HAE
Mar 22, 2022
Source:
Volume 105, April 2022, 108523
Pharmacological profile of PHA121 published in International Pharmacology
Jun 10, 2021
Clinical Data on Oral PHA121 Supporting the Prophylactic Treatment of Hereditary Angioedema
Jun 04, 2021
Pharvaris Presents Pharmacokinetic and Pharmacodynamic Data for Oral PHA121, Under Development for the Treatment of HAE
Feb 26, 2021
Pharmacodynamic Activity of Oral PHA121, Under Development for the Treatment of HAE
Nov 13, 2020
PHA-022121, a Selective Bradykinin-B2-Receptor Antagonist, Is Safe and Shows Rapid Oral Bioavailability in Humans
Nov 13, 2020
Bradykinin Challenge Provides Surrogate Endpoints For Hereditary Angioedema Treatment
Jul 30, 2020
In Vitro Pharmacological Profile of a New Small Molecule Bradykinin B2 Receptor Antagonist
Apr 09, 2020
PHA-022121, a First in Class Oral Bradykinin B2 Receptor Antagonist in Clinical Development: Proof of Concept Study in a Translational Monkey Bradykinin Challenge Model